CA1340750C - Haemostatic wound dressing material - Google Patents

Haemostatic wound dressing material

Info

Publication number
CA1340750C
CA1340750C CA 606856 CA606856A CA1340750C CA 1340750 C CA1340750 C CA 1340750C CA 606856 CA606856 CA 606856 CA 606856 A CA606856 A CA 606856A CA 1340750 C CA1340750 C CA 1340750C
Authority
CA
Canada
Prior art keywords
wound dressing
alginate
dressing material
material according
coating
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
CA 606856
Other languages
French (fr)
Inventor
Leslie J. Squires
Michael P. W. Harris
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Johnson and Johnson Patient Care Inc
Original Assignee
Johnson and Johnson Patient Care Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to GB8818114 priority Critical
Priority to GB888818114A priority patent/GB8818114D0/en
Application filed by Johnson and Johnson Patient Care Inc filed Critical Johnson and Johnson Patient Care Inc
Application granted granted Critical
Publication of CA1340750C publication Critical patent/CA1340750C/en
Anticipated expiration legal-status Critical
Application status is Expired - Lifetime legal-status Critical

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION, OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS, OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS, OR SURGICAL ARTICLES
    • A61L15/00Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
    • A61L15/16Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
    • A61L15/22Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing macromolecular materials
    • A61L15/28Polysaccharides or their derivatives

Abstract

A wound dressing material, comprises a fibrous substrate, such as a needled polyester fleece, having a discontinuous coating of a pharmaceutically acceptable alginate on a surface thereof.

Description

,~~.
1~4~~~a HAEMOSTATI(_ WOUND DRESSING MATERIAL
This invention relates to a haemostatic wound dressing material, and more particularly to a fibrous wound dressing . material which i~; coated with an alginate. The invention also provides wound dressings comprising such materials, and methods for their manufacture.
Alginates have long been recognised as useful in wound l0 dressings, because of their haemostatic properties. U.S.
Patent Specification No. 2512616 observes that alginates exist in several physical forms, but indicates that fibrous forms are preferred for use in surgical dressings.
Alginates woven into a gauze or in the form of loose wool similar to absorbent cotton are particularly identified as being useful.
British Patent Specification No. 629419 discloses a haemostatic surgical dressing which is formed by impregnating a cotton gauze or other fibrous material with relatively large quantities of an insoluble alginate.
British Patent Specification 1329693 also discloses a surgical dressing comprising an alginate as a haemostat.
In this case, the alginate is combined with a water-soluble polymer such a;s polyvinylacetate/polyvinyl-pyrrolidine copolymer, sodium carboxy methyl cellulose, polyethylene oxide, a poly(ga:Lactose methacrylate), a poly(galactose acrylate), a copolymer of methyl vinyl ether and malefic anhydride , or allantoin polygalacturonic acid. Such a water-soluble polymer is apparently used to allow the alginate to be cast or spread in the form of a film, sheet ' 2 or block of haemostatic material. This is said to have the advantage that th~~ film, sheet or block slowly dissolves in contact with a wound or burn to release the alginate which is then free to exhibit its haemostatic properties.
British Patent Specification No. 1329693 further discloses that the alginate/water-soluble polymer mixture may be cast onto a PVC sheet or, in some examples, onto a sheet of Polyweb Net 909 (Smith & Nephew). The latter is a wound-release layer which is widely used in wound dressings.
The dressings proposed in the above-mentioned British Patent specifications do not appear to be commercially available. Currently, alginates are available for use in wound treatment in two principal forms, namely fibrous wads and powder sprays.
The commercially available alginate fibre wads generally use relatively high amounts (typically greater than 100 g/mz of wet spun fibres), and are consequently expensive.
Further expense is incurred if the wads are needled to increase their into=grity.
Alginate powder sprays, such ~s are described in British Patent Specification No. 1254534, represent a convenient way of administering a haemostat rapidly to the surface of a wound. However, the use of such sprays provides no protection to a wound, and they cannot therefore be regarded as providing an alternative to a conventional wound dressing.
r ,:1 ~',.,.~.

According to the present invention, there is provided a wound dressing material comprising a fibrous substrate having a discontinuous coating of a pharmaceutically acceptable alginate deposited on a surface thereof.
By applying the alginate coating directly to the surface of a fibrous substrate, a very large surface area of alginate in relation to its weight can be achieved. This is of advantage in that, in contrast to the dressings disclosed in British Patent Specification No. 1329693, the alginate rapidly contacts and reacts with any blood from the wound to which the dressing material is applied. Effective haemostasis can therefore be obtained with relatively small amounts of alginate. The alginate (or alginate formulation) is preferably coated on the substrate at from 2 to 30 g/m2 dry weight, more preferably at from 5 g/m2 to g/m2, and most preferably at from 8 g/mz to 12 g/mz.
Surprisingly, these levels of alginate also provide 20 significant wound--release properties, so that a separate wound-release layer (such as a perforated plastics film or plastics net of the type commonly used in wound dressings) is not required.
Any material suitable for use as a wound-contacting absorbent may be used as the substrate. Materials used as wound-contacting absorbent layers can be woven, knitted or non-woven structures, and may be composed of any suitable fibre. Cotton, rayon, acrylic, polypropylene and polyester fibres are examples of suitable fibre types and may be used alone or in mixturE:s .
r 134Q75a The surface of the fibrous substrate may, if desired, be rendered more amenable to wound-release, for example by hot-calendering the surface fibres, especially with thermofusible fibres. It will be appreciated, of course, that such hot-calendering, if used, should not be to such a degree that the :surface of the substrate completely loses its fibrous character.
The preferred fabric for use in the wound dressing material to of the present invention is 100% polyester Malifleece within the weight range 100 g/m2 to 200 g/m2 (Ledatec Limited). Polyester tends to resist wet-collapse more than rayon, and hence makes a resilient pad which provides a degree of protection by cushioning the wound.
The alginate coating may comprise any pharmaceutically acceptable cationic alginate, such as sodium, calcium, potassium and ammonium alginates or mixtures of these.
Sodium and calcium alginates and their mixtures are preferred.
The haemostatic effect of 100% sodium alginate coatings may be increased by :substituting some of the sodium ions by calcium ions. 7.2% calcium, based on the weight of sodium alginate, is required for complete substitution of the sodium ions by the calcium. However, suitable gels are formed with much lower levels of ion exchange, for example from 1 to 3% calcium by weight of alginate, and preferably from 1.5 to 2.5% calcium by weight.
Since it is not desired to form a continuous film of alginate on the :substrate, there is no need to include 4a 1340'50 film-forming waf=er-soluble polymers in the alginate coating. Indeed, it is preferred that the alginate coating contain less than 40% by weight of other polymers, and more preferably less than :L5% by weight. It is particularly preferred that no more than 5% by weight of other polymers be included in the alginate coatings, because their presence may interfere with the haemostatic effect of the alginate.
l0 In the absence of substantial quantities of a film-forming polymer, alginates tend to be rather friable, and the alginate coating in the wound dressing material of the present invention therefore preferably also contains a plasticiser such as ethylene .glycol, propylene glycol or hexylene glycol, or an alkyl citrate or an appropriate mixture. The preferred plasticiser is glycerol (propan-1,2,3-triol). Th.e plasticiser may constitute from 0% to 80% by weight of t:he coating, and preferably from 10 to 70%
by weight. It is particularly preferred that the plasticiser be present in the coating in an amount between and 60% by weight.
The alginate coating may optionally incorporate other additives such as antiseptics, analgesics or other 25 medicaments, preferably in amounts less than 5% by weight, more preferably less than 2% by weight, and most preferably i~~
1340' 50 less than 1% by weight.
Other additives may also be desirable as processing aids.
For example, if a sodium/calcium alginate coating is 5 required, a viscous aqueous solution of sodium alginate can be prevented from forming an immediate gel in the presence of calcium ions by the inclusion of pH controlling materials such as glucono lactone or adipic acid/sequestering agent (e.g. sodium citrate) . Such materials are typically used in amounts of from 1 to 10% by weight, and preferably from 2.5 to 7.5% by weight. A preservative may also be added to increase resistance to microbial attack of the alginate.
Examples of suitable preservatives are Metasol*D3T (Merck), Parasept*(methyl paraben) (Kaloma Chemical) and Bronopol*(2-bromo-2-2-nit:ropropane-1,3 diol) (Boots Ltd.). Typical ranges for the amount of preservative are from 0.1% to 5.0%
by weight, and preferably from 0.25 to 1.0% by weight.
When an alginate coating is applied to a fibrous substrate in accordance with the invention, the individual fibres which lie close to the surface of the substrate are at least partly coated. Also, extremely thin films of alginate may be formed between adjacent fibres near points of crossover.
A discrete film or layer of alginate on the surface of the substrate is avoided, so that the permeability of the substrate to gases (such as air and water vapour) is not lost. Coating techniques which are suitable for achieving such a distribution include knife-over-roll, Meyer rod, screen printing and reverse roll coating. Reverse roll coating is particularly suitable, because it allows controlled amounts of material to be applied to a given area of substrate, even with substrates having variable and uneven surfaces.
The alginate is preferably applied to the substrate as a viscous aqueous, or substantially aqueous, fluid. The viscosity of the aqueous suspension of the alginate composif:ion may be adjusted to suit the coating technique * Trade-mark ,l & ,l 1 2 6 5 employed, but for reverse roll coating viscosities in the range 2000 cp to 30,000 cp, and preferably from 3000 cp to ... 8000 cp are .appropriate. Control of the nip-gap and of the casting ratio determines the amount of coating material applied to the substrate, as is well known in the coating art.
For reverse roll coating, the nip gap between the doctor roll and the applicator roll is typically from 0.075 to 0.45 mm, and preferably from 0.10 to 0.30 mm, e.g. from 0.15 to 0.20 mm.
The casting ratio (i.e. the ratio of the applicator roll peripheral speed to the backing roll peripheral speed) is generally in the range 0.8:1 to 1.7:1, and more preferably in the range 1:1 to 1.5:1, e.g. 1.2:1 Evaporation of the water phase may be achieved by any suitable means, for example by passage through temperature-controlled ovens. The oven is suitably at a temperature of from 100 to 150°C, e.g, from 110 to 140°C. If desired, a gradually increasing oven temperature may be employed.
Drying will typically take from 1 to 10 minutes, and more usually from 2 to 5 minutes.
The alginate-coated wound dressing material of the invention preferably has a gas permeability (as defined herein) which is at least 50% of the gas permeability of the material prior to coating with alginate. More preferably, the gas permeability of the coated material is from 60% to 98% of the permeability of the uncoated material, and most preferably from 75% to 95%, eg. from 85% to 92.5%.
The term "ga;s permeability" refers to the permeability of a wound dre:~sing material to cyclohexane vapour, which (unlike water vapour) is inert to the alginate and will not cause the alginate to swell. The test method is as follows:
J&J 1265 1340'50 ml of cyclohexane~ is placed in a 4 em diameter cylindrical test cell, which is then closed using a layer of the test material. The cell is placed in a fume cupboard at 25° a.nd the rate of loss of cyclohexane vapour 5 is measured by w<~ighing the cell periodically (eg. hourly for 5 hrs). Permeability may conveniently be expressed in terms of grams of cyclohexane lost/m2/24 hrs.
Typically, the wound dressing materials of the present l0 invention have a gas permeability of from 2500 to 20000 g/m2/24 hrs, and more preferably from 4000 to 15000 g/m2/24 hrs. Particularly preferred are dressing materials having a gas permeability of from 5000 to 10000 g/mz/24 hrs.
The wound dressing materials of the present invention are suitable for use :in a variety of forms. For example, they may be used either alone (being secured in place by bandaging, adhesiz~e tape, or any other suitable means), or they may be formed into composite dressings. Indeed, the material of the present invention can advantageously be used in any of the circumstances in which absorbent wound dressing pads are conventionally used. They are particularly suitable for use as post-operative dressings.
Composite dressings inc:Luding the dressing material of the present invention will. generally comprise a fibrous pad having an alginatE~ coating on one surface, and a backing material secured to the opposed surface. The backing material may be porous or non-porous, but materials which 3o are impermeable to water but permeable to water vapour are particularly preferred. Such materials include, for example, cast polyurethane films. Alternatively, the X

backing material may be a perforated plastics film, such as those conventionally used in first-aid dressings.
Wound dressings comprising the wound dressing material of the present invention will generally be supplied in sterile form, contained in a bacteria-proof envelope. Such envelopes may be of any conventional form, such as a pouch formed from two superimposed layers of plastics film, heat-sealed around the_Lr periphery.
to Sterilisation may be achieved by any conventional means, such as by autoclaving, gamma-irradiation and ethylene oxide treatment.
The invention is further described by reference to the following example.

An alginate composition having the following formulation 2o was prepared by simple mixing of the listed components:
%w/w Sodium alginate 1.96 Calcium orthophosphate 0.17 Glucono lactone 0.17 Glycerol 1.34 Bronopol 0.02 Water 96.34 The ratio of calcium ions to sodium ions in this formulation is 46.~5/53.4.

8a The composition was reverse roll coated onto the surface of Malifleece P/175/15 fabric, which is a 100°s polyester fabric of weight 175 g/m2. The coating conditions were chosen to produce a coating weight of 273 g/m2, which after drying in an oven at a temperature increasing from 110°C to 130°C for 5 minutes, yielded a dry coating weight of 10 g/m2.
Scanning electron microscopy showed the alginate coating to l0 form extremely thin films between individual fibres, with very little effect on the overall porosity of the fabric.
This can clearly be seen from Figures 1, 2 and 3, which are micrographs at magnifications of 13X, 31X and 67X, ,..
,- :, respectively.
1340'~~0 The coated material was found to be highly effective as a wound dressing. Not only was the small amount of alginate found to give effective haemostasis, but it also significantly improved release of the dressing from the wound, as compared with uncoated Malifleece fabric.

The composition described in Example 1 above was applied to two samples of 150 g/m2 polyester Malifleece fabric at a rate of 10 ~g/mZ. In the first case, the alginate was applied to the smooth surface of the fabric, while in the second case t:he alginate was applied to the opposite, less dense, surface. The gas permeability of the two samples and of the uncoated Malifleece fabric was measured using the test described above. The results were as follows:
S<~mple Gas Permeability 1 0400 g/m2/24 hr uncoated fabric fabric coated on smooth surface 7600 g/m2/24 hr fabric coatec! on less dense surface 7800 g/m2/24 hr Example 2 above was repeated, using a knitted hydrophobic polyester fabric. The coating conditions were selected to achieve a coating rate of 30 g/m2 on the smooth surface, but the same coating conditions gave a coating rate of 25 g/m2 when applied to the raised surface. It is thought that the different structure of the raised surface simply results in a lower pick-up of the alginate solution from the applicator roll.
Sample Gas Permeability uncoated fabric 9800 g/m2/24 hr fabric coated on smooth surface 5400 g/m2/24 hr fabric coated on raised surface 4900 g/m2/24 hY
,!&J 1 %65 -~- . 134070 i0 This example illustrates that a coating weight as high as 30 g/m2 can :be applied to a knitted hydrophobic polyester fabric while retaining 50% of the gas permeability of the fabric.
It will be understood that the present invention has been described above purely by way of example, and many variations will be possible within the scope of the invention.
J &J 1 265

Claims (10)

1. A wound dressing material consisting of a fibrous substrate having a discontinuous coating of a pharmaceutically acceptable alginate on a surface thereof.
2. A wound dressing material according to claim 1, wherein the alginate is selected from calcium, sodium, potassium and ammonium alginates and mixtures thereof.
3. A wound dressing material according to claim 1, wherein the alginate is present on the surface of the substrate in an amount of from 5 g/m2 to 20 g/m2.
4. A wound dressing material according to any one of claims 1, 2 or 3, wherein the coating additionally comprises from 10 to 70% by weight of plasticizer.
5. A wound dressing material according to any one of claims 1, 2 or 3, wherein the coating additionally comprises an antiseptic, an analgesic or a pH
controlling agent.
6. A wound dressing material according to any one of claims 1, 2 or 3, wherein the coating comprises a mixture of sodium and calcium alginates, having a ratio of calcium ions to sodium ions of from 20:80 to 80:20.
7. A wound dressing material according to any one of claims 1, 2 or 3, wherein the substrate is a woven, knitted or non-woven fabric.
8. A wound dressing material according to any one of claims 1, 2 or 3, wherein the substrate comprises cotton, rayon, acrylic, polypropylene or polyester fibers or a mixture thereof.
9. A wound dressing comprising a wound dressing material according to any one of claims 1, 2 or 3.
10. A method of making a wound dressing material according to any one of claims 1, 2 or 3, comprising coating a fibrous substrate with an aqueous dispersion of a pharmaceutically acceptable alginate, and subsequently drying the coated substrate under conditions to produce a discontinuous coating thereon.
CA 606856 1988-07-29 1989-07-27 Haemostatic wound dressing material Expired - Lifetime CA1340750C (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
GB8818114 1988-07-29
GB888818114A GB8818114D0 (en) 1988-07-29 1988-07-29 Haemostatic wound dressing material

Publications (1)

Publication Number Publication Date
CA1340750C true CA1340750C (en) 1999-09-14

Family

ID=10641332

Family Applications (1)

Application Number Title Priority Date Filing Date
CA 606856 Expired - Lifetime CA1340750C (en) 1988-07-29 1989-07-27 Haemostatic wound dressing material

Country Status (7)

Country Link
JP (1) JPH039761A (en)
AU (1) AU634164B2 (en)
CA (1) CA1340750C (en)
GB (2) GB8818114D0 (en)
IE (1) IE63408B1 (en)
NL (1) NL8901936A (en)
ZA (1) ZA8905796B (en)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9102660D0 (en) * 1991-02-07 1991-03-27 Ultra Lab Ltd Wound dressing materials
GB2276819B (en) * 1993-03-23 1996-12-11 Johnson & Johnson Medical Aqueous wound treatment composition comprising a polysaccharide and hexylene glycol
GB9400994D0 (en) * 1994-01-20 1994-03-16 Squibb Bristol Myers Co Wound dressing
GB9421653D0 (en) 1994-10-27 1994-12-14 Innovative Tech Ltd Wound dressing
GB9609474D0 (en) * 1996-05-08 1996-07-10 Innovative Tech Ltd Hydrogels
GB9813529D0 (en) * 1998-06-23 1998-08-19 Courtaulds Plc Nonwoven fabrics and their manufacture and use
US20070009586A1 (en) * 2000-02-29 2007-01-11 Cohen Kelman I Wound dressings containing complexes of transition metals and alginate for elastase sequestering
GB2377177A (en) * 2001-07-05 2003-01-08 Acordis Speciality Fibres Ltd Wound dressing comprising gel forming and superabsorbent layers
AT344059T (en) * 2003-01-06 2006-11-15 Speciality Fibres And Material Alginate fabric and super absorption containing wound pattern
US7910130B2 (en) 2004-11-30 2011-03-22 Tissue Technologies Holdings, Llc Starch derivatives and other derivatives, production processes therefor, and wound healing applications therefor
FR2907330B1 (en) * 2006-10-20 2009-11-27 Gilles Touati Device for protecting incision banks.
US8349354B2 (en) * 2009-09-22 2013-01-08 Ethicon, Inc. Composite layered hemostasis device
CN104144712A (en) * 2011-11-25 2014-11-12 株式会社大塚制药工场 Pharmaceutical composition useful for adhesion prevention or hemostasis
CN110621354A (en) * 2017-07-21 2019-12-27 矿物快速护理有限公司 Novel wound dressing for hemostasis

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB629419A (en) * 1946-12-05 1949-09-20 Johnson & Johnson Great Britai Improvements in and relating to surgical dressings
GB1329693A (en) * 1969-09-27 1973-09-12 Wallace Cameron Co Ltd Haemostatic surgical dressing and a method of manaufacturing same
GB1384537A (en) * 1971-05-20 1975-02-19 Sterling Winthrop Group Ltd Wound coverings
JPS527050B2 (en) * 1972-06-22 1977-02-26
GB1394742A (en) * 1972-08-03 1975-05-21 Medical Alginates Ltd Surgical dressing material
AT356285B (en) * 1977-06-30 1980-04-25 Bunzl & Biach Ag dressing
FR2402474B1 (en) * 1977-09-13 1982-01-08 Beghin Say Sa
GB1583367A (en) * 1978-05-19 1981-01-28 Samways B Wound coverings
GB2134792B (en) * 1983-02-11 1986-08-13 Inst Of Orthopaedics The Bioactive composite dressing
GB8609367D0 (en) * 1986-04-17 1986-05-21 Johnson & Johnson Adhesive wound dressing
JPH0649065B2 (en) * 1986-05-30 1994-06-29 アルケア株式会社 Skin damage surface protective material

Also Published As

Publication number Publication date
IE892466L (en) 1990-01-29
ZA8905796B (en) 1991-03-27
NL8901936A (en) 1990-02-16
GB8917154D0 (en) 1989-09-13
AU634164B2 (en) 1993-02-18
AU3897389A (en) 1990-02-01
GB2221620B (en) 1991-09-04
JPH039761A (en) 1991-01-17
GB2221620A (en) 1990-02-14
GB8818114D0 (en) 1988-09-01
IE63408B1 (en) 1995-04-19

Similar Documents

Publication Publication Date Title
US3645835A (en) Moisture-vapor-permeable pressure-sensitive adhesive materials
EP0599589B1 (en) Wound dressing
US8728445B2 (en) Hydrogel Compositions
ES2200004T3 (en) Spirosorbent bands of wounds for regulation of exudates.
CA2030593C (en) Multi-layered dressing
CA2433968C (en) Hemostatic wound dressing and method of making same
CA1312396C (en) Hydrocolloid/adhesive composition
US5543151A (en) Medical pressure-sensitive adhesive and medical bandage formed using the same
JP3196933B2 (en) Surface cladded absorbent composite by fibrous of hot melt, their preparation and absorbent article
DE69633534T2 (en) Structured occlusive dressing
ES2244206T3 (en) Non-adherent sterile shop.
US6191335B1 (en) Dressings
EP1255575B2 (en) Foam/film composite medical articles
CA1066466A (en) Polyurethane foam surgical dressing
US5851461A (en) Method of producing polysaccharide foams
US10086106B2 (en) Clay-based hemostatic agents
CA1288696C (en) Antimicrobial dressing or drape material
DE60209813T2 (en) Hydrogel layer containing, absorbent wundband
EP2330152B1 (en) Highly absorbent composite compositions, absorbent sheets provided with the compositions, and process for producing the same
US5914125A (en) Wound dressing
EP1255574B1 (en) Foam-on-film medical articles
DE60217925T2 (en) Metallic silver containing wound associations
EP0251810B2 (en) Wound dressing
EP0402650A2 (en) Absorbent mixture, method of making same, and absorbent article including same
US5603948A (en) Active ingredient patch for low-melting and/or volatile active ingredients

Legal Events

Date Code Title Description
MKEX Expiry

Effective date: 20160914